Paratek Pharmaceuticals Inc expected to post a loss of 31 cents a share - Earnings Preview

Paratek Pharmaceuticals

28/07/2023 12:27

* Paratek Pharmaceuticals Inc  PRTK.OQ   PRTK.O  is expected
to show a rise in quarterly revenue when it reports  results on
August 1 (estimated). 
    * The Boston Massachusetts-based  company is expected to
report  a
14.2% increase in revenue to $33.85 million from $29.64 million
a year ago, according to the mean estimate from 3 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Paratek
Pharmaceuticals
Inc is for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 25.4%
in the last three months. ​
    * Wall Street's median 12-month price target for Paratek
Pharmaceuticals Inc is $2.15​, below​ its last closing price
of $2.19. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Mar. 31 2023  -0.42       -0.42      -0.35     Beat    16.7
 Dec. 31 2023  0.25        0.09       -0.12     Missed  -228.6
 Sep. 30 2022  -0.31       -0.29      -0.38     Missed  -31​
 Jun. 30 2022  -0.33       -0.34      -0.33     Beat    2
 ​​Mar.        -0.35       -0.35      -0.35     Met     0
 31 2022                                                
 Dec. 31 2021  -0.62       -0.41      -0.66     Missed  -60​
 Sep. 30 2021  -0.44       -0.45      -0.37     Beat    17.8
 Jun. 30 2021  0.35        0.32       0.20      Missed  -36.5
 This summary was machine generated July 28 at 11:27 GMT.  All
figures in US dollars  unless otherwise stated